- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03524898
NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma
NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma. A Multicenter Open-label Single Arm Phase Ib/IIa Trial
A clinical trial with biweekly regimen of gemcitabine and nab-paclitaxel for Soft tissue sarcomas (STSs).
A Promising antitumor activity in patients with metastatic STS has been reported with gemcitabine alone or in combination with taxanes including docetaxel and paclitaxel in pre-treated patients.
Nab-paclitaxel is a 130-nm albumin-bound formulation of paclitaxel particles (Celgene, Summit, NJ) which was designed to eliminate the toxicities associated with Cremophor®-EL. Nab-paclitaxel at equal dose of paclitaxel showed increased antitumor activity, enhanced endothelial cell transport and 33% higher intra-tumor paclitaxel concentration in preclinical models of solid tumor xenografts promising an advantageous pharmacokinetic profile In sarcoma, nab-paclitaxel demonstrated preclinical anti-tumor activity in rhabdomyosarcoma xenograft model. Local relapsed tumors following paclitaxel treatment proved to be paclitaxel-resistant but remained responsive to nab-paclitaxel.
These findings provide the rationale for further evaluation of nab-paclitaxel in combination with gemcitabine for soft tissue sarcoma treatment.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Soft tissue sarcomas (STSs) account for 1% of all human cancers and consist of at least 50 different histological subtypes which have different clinical behavior and response to chemotherapy. Patients with advanced disease (locally advanced or metastatic) have a somber prognosis with a median OS between 12 and 15 months.
Palliative chemotherapy is the mainstay of treatment in the metastatic setting, although in a small subset with limited metastases local treatment may be curative. First-line treatment for advanced soft-tissue sarcoma includes doxorubicin hydrochloride, alone or in combination with other chemotherapy agents (e.g., ifosfamide), or olaratumab. Beyond first line several agents have shown activity, including gemcitabine/docetaxel, trabectedin and pazopanib, though no standard regimen has been established.
Promising antitumor activity in patients with metastatic STS has been reported with gemcitabine alone or in combination with taxanes including docetaxel and paclitaxel in pre-treated patients.
Nab-paclitaxel is a 130-nm albumin-bound formulation of paclitaxel particles (Abraxane®, Celgene, Summit, NJ) which was designed to eliminate the toxicities associated with Cremophor EL®. Nab-paclitaxel at equal dose of paclitaxel showed increased antitumor activity, enhanced endothelial cell transport and 33% higher intra-tumor paclitaxel concentration in preclinical models of solid tumor xenografts promising an advantageous pharmacokinetic profile In sarcoma, nab-paclitaxel demonstrated preclinical antitumor activity in rhabdomyosarcoma xenograft model. Local relapsed tumors following paclitaxel treatment proved to be paclitaxel-resistant but remained responsive to nab-paclitaxel.
These findings provide the rationale for further evaluation of nab-paclitaxel in combination with gemcitabine for soft tissue sarcoma treatment.
Phase Ib objective:
- To assess the safety and feasibility of combining nab-paclitaxel and gemcitabine
Phase II objective:
- To determine whether or not gemcitabine/nab-paclitaxel regimen exhibits antitumor activity that is worth testing further in STS.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Basel, Switzerland, CH-4031
- Universitaetsspital Basel
-
Bellinzona, Switzerland, 6500
- Istituto Oncologico della Svizzera Italiana
-
Bern, Switzerland, CH-3010
- Inselspital, Bern
-
Chur, Switzerland, 7000
- Kantonsspital Graubünden
-
Geneva, Switzerland, CH-1211
- Hopital Cantonal Universitaire de Geneve
-
Lausanne, Switzerland, 1011
- CHUV - Swiss Cancer Center Lausanne
-
St. Gallen, Switzerland, 9007
- Kantonsspital St. Gallen
-
Zürich, Switzerland, 8091
- UniversitätsSpital Zürich
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically confirmed minimum grade 2, locally advanced or metastatic STS refractory to chemotherapy and not suitable for local treatment.
- Minimum one line and maximum 2 lines of previous chemotherapy for advanced/metastatic STS
- Measurable disease according to RECIST v1.1
- Age ≥ 18 years
- WHO performance status 0-2
- Adequate hematological, hepatic and renal function
- Negative pregnancy test
- Effective method of birth control
- Peripheral neuropathy at enrolment must be ≤ grade 1
Exclusion Criteria:
- Uncontrolled CNS metastases
- Previous or concomitant malignancy diagnosed within 3 years
- More than 2 lines of previous systemic treatment for STS
- Previous sarcoma treatment with gemcitabine and/or nab-paclitaxel or other taxanes
- Radiotherapy within 4 weeks prior to registration
- Concurrent or recent treatment with any other experimental drug
- Concomitant use of other anti-cancer drugs
- Severe or uncontrolled cardiovascular disease
- History of cerebrovascular accident or intracranial hemorrhage within 2 months prior to registration
- Evidence of active, noninfectious pneumonitis or history of interstitial lung disease
- Known history of human immunodeficiency virus (HIV) or active chronic Hepatitis C or Hepatitis B Virus infection or any uncontrolled active systemic infection
- Any concomitant drugs contraindicated for use with the trial drugs according to the approved product information
- Known hypersensitivity to the trial drug(s)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: nab-paclitaxel and gemcitabine
Treatment consists of the combination treatment of nab-paclitaxel and gemcitabine, which is given every 2 weeks during 28-day cycle intervals until disease progression.
|
150 mg/m2 / 125 mg/m2
Other Names:
1000 mg/m2
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase I: Dose-limiting toxicity (DLT)
Time Frame: during the first cycle of treatment (28 days)
|
DLT is defined as any of the following adverse events (AEs) occurring during the first cycle of treatment and regarded by the investigators and/or the Sponsor to be related to nab-paclitaxel and/or gemcitabine (AEs not related to the IMPs are not regarded as DLT)
|
during the first cycle of treatment (28 days)
|
Phase II: Progression-free rate (PFR)
Time Frame: at 12 weeks after registration
|
PFR at 12 weeks after registration determined by the percentage of progression-free patients at 12 weeks. Progression is defined as one of the following events (whichever occurs first):
|
at 12 weeks after registration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase I: PFR 12 weeks
Time Frame: at 12 weeks after registration
|
at 12 weeks after registration
|
|
Phase I: Best response assessed according to RECIST v1.1
Time Frame: assessed for up to 5 years after patient registration
|
assessed for up to 5 years after patient registration
|
|
Phase I: Adverse events (AEs), assessed according to NCI CTCAE v4.03
Time Frame: assessed for up to 5 years after patient registration
|
assessed for up to 5 years after patient registration
|
|
Phase II: Progression-free survival (PFS)
Time Frame: assessed for up to 5 years after patient registration
|
PFS defined as the time from registration until progression according to RECIST v1.1 or death from any cause, whichever occurs first. Patients without an event at the time of analysis and patients starting a new anticancer therapy in the absence of an event will be censored at the date of the last tumor assessment before the start of the new therapy, if any. |
assessed for up to 5 years after patient registration
|
Phase II: Overall Survival (OS)
Time Frame: assessed for up to 5 years after patient registration
|
OS defined as the time from registration until death from any cause.
Patients without an event at the time of analysis will be censored at the date they were last known to be alive.
|
assessed for up to 5 years after patient registration
|
Phase II: Best response assessed according to RECIST v1.1
Time Frame: assessed for up to 5 years after patient registration
|
assessed for up to 5 years after patient registration
|
|
Phase II: AEs, assessed according to NCI CTCAE v4.03
Time Frame: from registration until 28 days after administration of the last dose of trial treatment
|
from registration until 28 days after administration of the last dose of trial treatment
|
|
Phase II: Symptom-related quality of life assessed by questionnaires
Time Frame: assessed for up to 5 years after patient registration
|
Symptom-related quality of life will be assessed with the M.D. Anderson Symptom Inventory (MDASI), which measures the severity of 13 cancer-related symptoms and their impact on six dimensions of daily life at their worst in the last 24 hours on a 0-10 numerical rating scale, with 0 being "not present" and 10 being "as bad as you can imagine."
|
assessed for up to 5 years after patient registration
|
Phase II: Nab-paclitaxel related sensory neuropathy assessed by questionnaires
Time Frame: assessed for up to 5 years after patient registration
|
To address an important side-effect of nab-paclitaxel, sensory neuropathy will be assessed by the 4-item subscale of the FACT/GOG-Ntx (Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity), which measures the severity of sensory neuropathy in the last 7 days on a 0-4 numerical rating scale, with 0 being "not at all" and 4 being "very much."
|
assessed for up to 5 years after patient registration
|
Collaborators and Investigators
Investigators
- Study Chair: Christian Rothermundt, MD, Cantonal Hospital of St. Gallen
- Study Chair: Antonia Digklia, MD, Département d'Oncologie CHUV , Lausanne
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Sarcoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Gemcitabine
- Paclitaxel
Other Study ID Numbers
- SAKK 57/16 - NAPAGE
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Soft Tissue Sarcoma
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI)WithdrawnStage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage II Adult Soft Tissue Sarcoma | Stage IIA Adult Soft Tissue Sarcoma | Stage IIB Adult Soft Tissue Sarcoma | Stage IIC Adult Soft Tissue Sarcoma
-
CytRxUnknownUnresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Locally Advanced Soft Tissue SarcomaUnited States, Australia, Russian Federation, Hungary, India, Romania, Ukraine
-
National Institutes of Health Clinical Center (CC)CompletedRecurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IVA Adult Soft Tissue Sarcoma | Stage IIB Adult Soft Tissue Sarcoma | Stage IIC Adult Soft Tissue Sarcoma | Stage IVB Adult Soft Tissue Sarcoma
-
University of WashingtonAadi Bioscience, Inc.Active, not recruitingAdvanced Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Locally Advanced Soft Tissue SarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Alveolar Soft Part Sarcoma | Unresectable Alveolar Soft Part Sarcoma | Advanced Soft Tissue Sarcoma | Advanced Alveolar Soft Part SarcomaUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage I Adult Soft Tissue Sarcoma | Stage II Adult Soft Tissue SarcomaUnited States
-
Centre Leon BerardNovartis; National Cancer Institute, FranceRecruitingAdvanced Soft-tissue Sarcoma | Metastatic Soft-tissue SarcomaFrance
-
UNICANCERRecruitingAdvanced Soft-tissue Sarcoma | Metastatic Soft-tissue SarcomaFrance
-
University of Colorado, DenverAgenus Inc.RecruitingAdvanced Soft Tissue Sarcoma | Metastatic Soft Tissue SarcomaUnited States
-
Wake Forest University Health SciencesMerck Sharp & Dohme LLCCompletedSoft Tissue Sarcoma, Adult | Soft Tissue Sarcoma, ChildUnited States
Clinical Trials on Nab-Paclitaxel
-
Fudan UniversityActive, not recruitingTNBC - Triple-Negative Breast CancerChina
-
Shengjing HospitalRecruiting
-
M.D. Anderson Cancer CenterCelgene CorporationCompletedMelanoma | Liver MetastasisUnited States
-
HutchmedNot yet recruiting
-
Peking University Cancer Hospital & InstituteActive, not recruiting
-
Changhai HospitalRecruiting
-
Fundacion OncosurCompleted
-
Trishula Therapeutics, Inc.AbbVieRecruitingPancreatic CancerUnited States
-
AIO-Studien-gGmbHCelgene; ClinAssess GmbHCompletedResectable Pancreatic Cancer | Ductal Adenocarcinoma of the PancreasGermany
-
Fudan UniversityUnknownAdvanced Pancreatic CancerChina